Primmune Therapeutics

Primmune is harnessing innate immunity with best-in-class small molecule TLR7 agonists for oncology and viral diseases. Its oral compounds are designed to deliver systemic immune activation with favorable tolerability.

Location: San Diego, USA

Board director: Debora Dumont - Tom Heyman

Website:

primmunerx.com

Related news

2024-03-20

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

2023-10-11

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

2023-04-18

Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting

2023-03-14

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

2021-11-04

Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing

2021-11-02

Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™

2021-02-05

Primmune Therapeutics Strengthens Leadership Team with Key Appointments

2021-01-12

Primmune Therapeutics Announces Close of Series A Financing